Genetic susceptibility to breast cancer

Molecular Oncology

Volumn 4, Issue 3, 2010, Pages 174-191

  Mavaddat, Nasim ^a   Antoniou, Antonis C ^a   Easton, Douglas F ^a   Garcia Closas, Montserrat ^b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Aetiology of breast cancer; BRCA1 2 mutation carriers; Breast cancer; Genetic susceptibility; Pathology

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR RECEPTOR 2;

BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; PENETRANCE; POPULATION; PREDICTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; FEMALE; GENETIC POLYMORPHISM; GENETICS; MUTATION; PATHOLOGY; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HETEROZYGOTE; HUMANS; MUTATION; PENETRANCE; POLYMORPHISM, GENETIC;

EID: 77953872952     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2010.04.011     Document Type: Review

References (172)

1. van 't Veer L.J., Dai H., Van De Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., and Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 (2002) 530-536
2. Adnane J., Gaudray P., Dionne C.A., Crumley G., Jaye M., Schlessinger J., Jeanteur P., Birnbaum D., and Theillet C. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 6 (1991) 659-663
3. Ahmed S., Thomas G., Ghoussaini M., Healey C.S., Humphreys M.K., Platte R., Morrison J., Maranian M., Pooley K.A., Luben R., Eccles D., Evans D.G., Fletcher O., Johnson N., dos SS I., Peto J., Stratton M.R., Rahman N., Jacobs K., Prentice R., Anderson G.L., Rajkovic A., Curb J.D., Ziegler R.G., Berg C.D., Buys S.S., McCarty C.A., Feigelson H.S., Calle E.E., Thun M.J., Diver W.R., Bojesen S., Nordestgaard B.G., Flyger H., Dork T., Schurmann P., Hillemanns P., Karstens J.H., Bogdanova N.V., Antonenkova N.N., Zalutsky I.V., Bermisheva M., Fedorova S., Khusnutdinova E., Kang D., Yoo K.Y., Noh D.Y., Ahn S.H., Devilee P., van Asperen C.J., Tollenaar R.A., Seynaeve C., Garcia-Closas M., Lissowska J., Brinton L., Peplonska B., Nevanlinna H., Heikkinen T., Aittomaki K., Blomqvist C., Hopper J.L., Southey M.C., Smith L., Spurdle A.B., Schmidt M.K., Broeks A., van Hien R.R., Cornelissen S., Milne R.L., Ribas G., Gonzalez-Neira A., Benitez J., Schmutzler R.K., Burwinkel B., Bartram C.R., Meindl A., Brauch H., Justenhoven C., Hamann U., Chang-Claude J., Hein R., Wang-Gohrke S., Lindblom A., Margolin S., Mannermaa A., Kosma V.M., Kataja V., Olson J.E., Wang X., Fredericksen Z., Giles G.G., Severi G., Baglietto L., English D.R., Hankinson S.E., Cox D.G., Kraft P., Vatten L.J., Hveem K., Kumle M., Sigurdson A., Doody M., Bhatti P., Alexander B.H., Hooning M.J., van den Ouweland A.M., Oldenburg R.A., Schutte M., Hall P., Czene K., Liu J., Li Y., Cox A., Elliott G., Brock I., Reed M.W., Shen C.Y., Yu J.C., Hsu G.C., Chen S.T., Anton-Culver H., Ziogas A., Andrulis I.L., Knight J.A., Beesley J., Goode E.L., Couch F., Chenevix-Trench G., Hoover R.N., Ponder B.A., Hunter D.J., Pharoah P.D., Dunning A.M., Chanock S.J., and Easton D.F. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat. Genet. 41 (2009) 585-590
4. Amend K., Hicks D., and Ambrosone C.B. Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res. 66 (2006) 8327-8330
5. Amundadottir L.T., Thorvaldsson S., Gudbjartsson D.F., Sulem P., Kristjansson K., Arnason S., Gulcher J.R., Bjornsson J., Kong A., Thorsteinsdottir U., and Stefansson K. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med. 1 (2004) e65 229-236
6. Anderson W.F., Chatterjee N., Ershler W.B., and Brawley O.W. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res. Treat. 76 (2002) 27-36
7. Anderson W.F., and Matsuno R. Breast cancer heterogeneity: a mixture of at least two main types?. J. Natl. Cancer Inst. 98 (2006) 948-951
8. Andrieu N., Goldgar D.E., Easton D.F., Rookus M., Brohet R., Antoniou A.C., Peock S., Evans G., Eccles D., Douglas F., Nogues C., Gauthier-Villars M., Chompret A., van Leeuwen F.E., Kluijt I., Benitez J., Arver B., Olah E., and Chang-Claude J. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J. Natl. Cancer Inst. 98 (2006) 535-544
9. Antoniou A.C., and Easton D.F. Models of genetic susceptibility to breast cancer. Oncogene 25 (2006) 5898-5905
10. Antoniou A.C., Pharoah P.D., McMullan G., Day N.E., Stratton M.R., Peto J., Ponder B.J., and Easton D.F. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br. J. Cancer 86 (2002) 76-83
11. Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., Loman N., Olsson H., Johannsson O., Borg A., Pasini B., Radice P., Manoukian S., Eccles D.M., Tang N., Olah E., Anton-Culver H., Warner E., Lubinski J., Gronwald J., Gorski B., Tulinius H., Thorlacius S., Eerola H., Nevanlinna H., Syrjakoski K., Kallioniemi O.P., Thompson D., Evans C., Peto J., Lalloo F., Evans D.G., and Easton D.F. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72 (2003) 1117-1130
12. Antoniou A.C., Pharoah P.P., Smith P., and Easton D.F. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br. J. Cancer 91 (2004) 1580-1590
13. Antoniou A.C., Sinilnikova O.M., Simard J., Leone M., Dumont M., Neuhausen S.L., Struewing J.P., Stoppa-Lyonnet D., Barjhoux L., Hughes D.J., Coupier I., Belotti M., Lasset C., Bonadona V., Bignon Y.J., Rebbeck T.R., Wagner T., Lynch H.T., Domchek S.M., Nathanson K.L., Garber J.E., Weitzel J., Narod S.A., Tomlinson G., Olopade O.I., Godwin A., Isaacs C., Jakubowska A., Lubinski J., Gronwald J., Gorski B., Byrski T., Huzarski T., Peock S., Cook M., Baynes C., Murray A., Rogers M., Daly P.A., Dorkins H., Schmutzler R.K., Versmold B., Engel C., Meindl A., Arnold N., Niederacher D., Deissler H., Spurdle A.B., Chen X., Waddell N., Cloonan N., Kirchhoff T., Offit K., Friedman E., Kaufmann B., Laitman Y., Galore G., Rennert G., Lejbkowicz F., Raskin L., Andrulis I.L., Ilyushik E., Ozcelik H., Devilee P., Vreeswijk M.P., Greene M.H., Prindiville S.A., Osorio A., Benitez J., Zikan M., Szabo C.I., Kilpivaara O., Nevanlinna H., Hamann U., Durocher F., Arason A., Couch F.J., Easton D.F., and Chenevix-Trench G. RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am. J. Hum. Genet. 81 (2007) 1186-1200
14. Antoniou A.C., Cunningham A.P., Peto J., Evans D.G., Lalloo F., Narod S.A., Risch H.A., Eyfjord J.E., Hopper J.L., Southey M.C., Olsson H., Johannsson O., Borg A., Pasini B., Radice P., Manoukian S., Eccles D.M., Tang N., Olah E., Anton-Culver H., Warner E., Lubinski J., Gronwald J., Gorski B., Tryggvadottir L., Syrjakoski K., Kallioniemi O.P., Eerola H., Nevanlinna H., Pharoah P.D., and Easton D.F. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br. J. Cancer 98 (2008) 1457-1466
15. Antoniou A.C., Spurdle A.B., Sinilnikova O.M., Healey S., Pooley K.A., Schmutzler R.K., Versmold B., Engel C., Meindl A., Arnold N., Hofmann W., Sutter C., Niederacher D., Deissler H., Caldes T., Kampjarvi K., Nevanlinna H., Simard J., Beesley J., Chen X., Neuhausen S.L., Rebbeck T.R., Wagner T., Lynch H.T., Isaacs C., Weitzel J., Ganz P.A., Daly M.B., Tomlinson G., Olopade O.I., Blum J.L., Couch F.J., Peterlongo P., Manoukian S., Barile M., Radice P., Szabo C.I., Pereira L.H., Greene M.H., Rennert G., Lejbkowicz F., Barnett-Griness O., Andrulis I.L., Ozcelik H., Gerdes A.M., Caligo M.A., Laitman Y., Kaufman B., Milgrom R., Friedman E., Domchek S.M., Nathanson K.L., Osorio A., Llort G., Milne R.L., Benitez J., Hamann U., Hogervorst F.B., Manders P., Ligtenberg M.J., van den Ouweland A.M., Peock S., Cook M., Platte R., Evans D.G., Eeles R., Pichert G., Chu C., Eccles D., Davidson R., Douglas F., Godwin A.K., Barjhoux L., Mazoyer S., Sobol H., Bourdon V., Eisinger F., Chompret A., Capoulade C., Bressac-de P.B., Lenoir G.M., Gauthier-Villars M., Houdayer C., Stoppa-Lyonnet D., Chenevix-Trench G., and Easton D.F. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am. J. Hum. Genet. 82 (2008) 937-948
16. Antoniou A.C., Sinilnikova O.M., McGuffog L., Healey S., Nevanlinna H., Heikkinen T., Simard J., Spurdle A.B., Beesley J., Chen X., Neuhausen S.L., Ding Y.C., Couch F.J., Wang X., Fredericksen Z., Peterlongo P., Peissel B., Bonanni B., Viel A., Bernard L., Radice P., Szabo C.I., Foretova L., Zikan M., Claes K., Greene M.H., Mai P.L., Rennert G., Lejbkowicz F., Andrulis I.L., Ozcelik H., Glendon G., Gerdes A.M., Thomassen M., Sunde L., Caligo M.A., Laitman Y., Kontorovich T., Cohen S., Kaufman B., Dagan E., Baruch R.G., Friedman E., Harbst K., Barbany-Bustinza G., Rantala J., Ehrencrona H., Karlsson P., Domchek S.M., Nathanson K.L., Osorio A., Blanco I., Lasa A., Benitez J., Hamann U., Hogervorst F.B., Rookus M.A., Collee J.M., Devilee P., Ligtenberg M.J., van der Luijt R.B., Aalfs C.M., Waisfisz Q., Wijnen J., van Roozendaal C.E., Peock S., Cook M., Frost D., Oliver C., Platte R., Evans D.G., Lalloo F., Eeles R., Izatt L., Davidson R., Chu C., Eccles D., Cole T., Hodgson S., Godwin A.K., Stoppa-Lyonnet D., Buecher B., Leone M., Bressac-de P.B., Remenieras A., Caron O., Lenoir G.M., Sevenet N., Longy M., Ferrer S.F., Prieur F., Goldgar D., Miron A., John E.M., Buys S.S., Daly M.B., Hopper J.L., Terry M.B., Yassin Y., Singer C., Gschwantler-Kaulich D., Staudigl C., Hansen T.O., Barkardottir R.B., Kirchhoff T., Pal P., Kosarin K., Offit K., Piedmonte M., Rodriguez G.C., Wakeley K., Boggess J.F., Basil J., Schwartz P.E., Blank S.V., Toland A.E., Montagna M., Casella C., Imyanitov E.N., Allavena A., Schmutzler R.K., Versmold B., Engel C., Meindl A., Ditsch N., Arnold N., Niederacher D., Deissler H., Fiebig B., Suttner C., Schonbuchner I., Gadzicki D., Caldes T., de la Hoya M., Pooley K.A., Easton D.F., and Chenevix-Trench G. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum. Mol. Genet. 18 (2009) 4442-4456
17. Armes J.E., Egan A.J., Southey M.C., Dite G.S., McCredie M.R., Giles G.G., Hopper J.L., and Venter D.J. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 83 (1998) 2335-2345
18. Armes J.E., Trute L., White D., Southey M.C., Hammet F., Tesoriero A., Hutchins A.M., Dite G.S., McCredie M.R., Giles G.G., Hopper J.L., and Venter D.J. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res. 59 (1999) 2011-2017
19. Barnhart B.C., Lee J.C., Alappat E.C., and Peter M.E. The death effector domain protein family. Oncogene 22 (2003) 8634-8644
20. Bartkova J., Tommiska J., Oplustilova L., Aaltonen K., Tamminen A., Heikkinen T., Mistrik M., Aittomaki K., Blomqvist C., Heikkila P., Lukas J., Nevanlinna H., and Bartek J. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol. Oncol. 2 (2008) 296-316
21. Begg C.B. On the use of familial aggregation in population-based case probands for calculating penetrance. J. Natl. Cancer Inst. 94 (2002) 1221-1226
22. Begg C.B., Haile R.W., Borg A., Malone K.E., Concannon P., Thomas D.C., Langholz B., Bernstein L., Olsen J.H., Lynch C.F., Anton-Culver H., Capanu M., Liang X., Hummer A.J., Sima C., and Bernstein J.L. Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299 (2008) 194-201
23. Birch J.M., Alston R.D., McNally R.J., Evans D.G., Kelsey A.M., Harris M., Eden O.B., and Varley J.M. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20 (2001) 4621-4628
24. de Bock G.H., Mourits M.J., Schutte M., Krol-Warmerdam E.M., Seynaeve C., Blom J., Brekelmans C.T., Meijers-Heijboer H., van Asperen C.J., Cornelisse C.J., Devilee P., Tollenaar R.A., and Klijn J.G. Association between the CHEK2*1100delC germ line mutation and estrogen receptor status. Int. J. Gynecol. Cancer 16 Suppl. 2 (2006) 552-555
25. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 2006, 98:1382-1396.
26. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., Karaca G., Troester M.A., Tse C.K., Edmiston S., Deming S.L., Geradts J., Cheang M.C., Nielsen T.O., Moorman P.G., Earp H.S., and Millikan R.C. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295 (2006) 2492-2502
27. Cavdar K.E., Burkhart W., Blackburn K., Moseley A., and Spremulli L.L. The small subunit of the mammalian mitochondrial ribosome. Identification of the full complement of ribosomal proteins present. J. Biol. Chem. 276 (2001) 19363-19374
28. Cavdar K.E., Ranasinghe A., Burkhart W., Blackburn K., Koc H., Moseley A., and Spremulli L.L. A new face on apoptosis: death-associated protein 3 and PDCD9 are mitochondrial ribosomal proteins. FEBS Lett. 492 (2001) 166-170
29. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004, 74:1175-1182.
30. Chen J.J., Silver D., Cantor S., Livingston D.M., and Scully R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res. 59 (1999) 1752s-1756s
31. Chen Y., Choong L.Y., Lin Q., Philp R., Wong C.H., Ang B.K., Tan Y.L., Loh M.C., Hew C.L., Shah N., Druker B.J., Chong P.K., and Lim Y.P. Differential expression of novel tyrosine kinase substrates during breast cancer development. Mol. Cell Proteomics 6 (2007) 2072-2087
32. Chlebowski R.T., Chen Z., Anderson G.L., Rohan T., Aragaki A., Lane D., Dolan N.C., Paskett E.D., McTiernan A., Hubbell F.A., Adams-Campbell L.L., and Prentice R. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J. Natl. Cancer Inst. 97 (2005) 439-448
33. Chu K.C., and Anderson W.F. Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Cancer Res. Treat. 74 (2002) 199-211
34. Clayton D.G. Prediction and interaction in complex disease genetics: experience in type 1 diabetes. PLoS Genet. 5 (2009) e1000540 1-6
35. Colditz G.A., Rosner B.A., Chen W.Y., Holmes M.D., and Hankinson S.E. Risk factors for breast cancer according to estrogen and progesterone receptor status. J. Natl. Cancer Inst. 96 (2004) 218-228
36. Cortesi L., Turchetti D., Bertoni C., Bellei R., Mangone L., Vinceti M., Federico M., Silingardi V., and Ferrari S. Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations. Genes Chromosomes Cancer 27 (2000) 130-135
37. Cotterchio M., Kreiger N., Theis B., Sloan M., and Bahl S. Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 1053-1060
38. Couch F.J., Sinilnikova O., Vierkant R.A., Pankratz V.S., Fredericksen Z.S., Stoppa-Lyonnet D., Coupier I., Hughes D., Hardouin A., Berthet P., Peock S., Cook M., Baynes C., Hodgson S., Morrison P.J., Porteous M.E., Jakubowska A., Lubinski J., Gronwald J., Spurdle A.B., Schmutzler R., Versmold B., Engel C., Meindl A., Sutter C., Horst J., Schaefer D., Offit K., Kirchhoff T., Andrulis I.L., Ilyushik E., Glendon G., Devilee P., Vreeswijk M.P., Vasen H.F., Borg A., Backenhorn K., Struewing J.P., Greene M.H., Neuhausen S.L., Rebbeck T.R., Nathanson K., Domchek S., Wagner T., Garber J.E., Szabo C., Zikan M., Foretova L., Olson J.E., Sellers T.A., Lindor N., Nevanlinna H., Tommiska J., Aittomaki K., Hamann U., Rashid M.U., Torres D., Simard J., Durocher F., Guenard F., Lynch H.T., Isaacs C., Weitzel J., Olopade O.I., Narod S., Daly M.B., Godwin A.K., Tomlinson G., Easton D.F., Chenevix-Trench G., and Antoniou A.C. AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 1416-1421
39. Cox A., Dunning A.M., Garcia-Closas M., Balasubramanian S., Reed M.W., Pooley K.A., Scollen S., Baynes C., Ponder B.A., Chanock S., Lissowska J., Brinton L., Peplonska B., Southey M.C., Hopper J.L., McCredie M.R., Giles G.G., Fletcher O., Johnson N., dos SS I., Gibson L., Bojesen S.E., Nordestgaard B.G., Axelsson C.K., Torres D., Hamann U., Justenhoven C., Brauch H., Chang-Claude J., Kropp S., Risch A., Wang-Gohrke S., Schurmann P., Bogdanova N., Dork T., Fagerholm R., Aaltonen K., Blomqvist C., Nevanlinna H., Seal S., Renwick A., Stratton M.R., Rahman N., Sangrajrang S., Hughes D., Odefrey F., Brennan P., Spurdle A.B., Chenevix-Trench G., Beesley J., Mannermaa A., Hartikainen J., Kataja V., Kosma V.M., Couch F.J., Olson J.E., Goode E.L., Broeks A., Schmidt M.K., Hogervorst F.B., Van't Veer L.J., Kang D., Yoo K.Y., Noh D.Y., Ahn S.H., Wedren S., Hall P., Low Y.L., Liu J., Milne R.L., Ribas G., Gonzalez-Neira A., Benitez J., Sigurdson A.J., Stredrick D.L., Alexander B.H., Struewing J.P., Pharoah P.D., and Easton D.F. A common coding variant in CASP8 is associated with breast cancer risk. Nat. Genet. 39 (2007) 352-358
40. Cullinane C.A., Lubinski J., Neuhausen S.L., Ghadirian P., Lynch H.T., Isaacs C., Weber B., Moller P., Offit K., Kim-Sing C., Friedman E., Randall S., Pasini B., Ainsworth P., Gershoni-Baruch R., Foulkes W.D., Klijn J., Tung N., Rennert G., Olopade O., Couch F., Wagner T., Olsson H., Sun P., Weitzel J.N., and Narod S.A. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int. J. Cancer 117 (2005) 988-991
41. Cunningham, J.E., Montero, A.J., Garrett-Mayer, E., Berkel, H.J., Ely, B, 2009. Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes Control.
42. Cybulski C., Wokolorczyk D., Gliniewicz B., Sikorski A., Gorski B., Jakubowska A., Huzarski T., Byrski T., Debniak T., Gronwald J., Lubinski J., and Narod S.A. A six-nucleotide deletion in the CASP8 promoter is not associated with a susceptibility to breast and prostate cancers in the Polish population. Breast Cancer Res. Treat. 112 (2008) 367-368
43. Cybulski C., Huzarski T., Byrski T., Gronwald J., Debniak T., Jakubowska A., Gorski B., Wokolorczyk D., Masojc B., Narod S.A., and Lubinski J. Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention. Clin. Genet. 75 (2009) 72-78
44. De V.G., Verderio P., Pizzamiglio S., Manoukian S., Barile M., Fortuzzi S., Ravagnani F., Pierotti M.A., Radice P., and Peterlongo P. Evidences for association of the CASP8 -652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases. Breast Cancer Res. Treat. 113 (2009) 607-608
45. Dickson C., Spencer-Dene B., Dillon C., and Fantl V. Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors. Breast Cancer Res. 2 (2000) 191-196
46. Easton D.F. Familial risks of breast cancer. Breast Cancer Res. 4 (2002) 179-181
47. Easton D.F., and Eeles R.A. Genome-wide association studies in cancer. Hum. Mol. Genet. 17 (2008) R109-R115
48. Easton D.F., Bishop D.T., Ford D., and Crockford G.P. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 52 (1993) 678-701
49. Easton D.F., Pooley K.A., Dunning A.M., Pharoah P.D., Thompson D., Ballinger D.G., Struewing J.P., Morrison J., Field H., Luben R., Wareham N., Ahmed S., Healey C.S., Bowman R., Meyer K.B., Haiman C.A., Kolonel L.K., Henderson B.E., Le M.L., Brennan P., Sangrajrang S., Gaborieau V., Odefrey F., Shen C.Y., Wu P.E., Wang H.C., Eccles D., Evans D.G., Peto J., Fletcher O., Johnson N., Seal S., Stratton M.R., Rahman N., Chenevix-Trench G., Bojesen S.E., Nordestgaard B.G., Axelsson C.K., Garcia-Closas M., Brinton L., Chanock S., Lissowska J., Peplonska B., Nevanlinna H., Fagerholm R., Eerola H., Kang D., Yoo K.Y., Noh D.Y., Ahn S.H., Hunter D.J., Hankinson S.E., Cox D.G., Hall P., Wedren S., Liu J., Low Y.L., Bogdanova N., Schurmann P., Dork T., Tollenaar R.A., Jacobi C.E., Devilee P., Klijn J.G., Sigurdson A.J., Doody M.M., Alexander B.H., Zhang J., Cox A., Brock I.W., MacPherson G., Reed M.W., Couch F.J., Goode E.L., Olson J.E., Meijers-Heijboer H., van den Ouweland A., Uitterlinden A., Rivadeneira F., Milne R.L., Ribas G., Gonzalez-Neira A., Benitez J., Hopper J.L., McCredie M., Southey M., Giles G.G., Schroen C., Justenhoven C., Brauch H., Hamann U., Ko Y.D., Spurdle A.B., Beesley J., Chen X., Mannermaa A., Kosma V.M., Kataja V., Hartikainen J., Day N.E., Cox D.R., and Ponder B.A. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447 (2007) 1087-1093
50. Eisinger F., Nogues C., Guinebretiere J.M., Peyrat J.P., Bardou V.J., Noguchi T., Vennin P., Sauvan R., Lidereau R., Birnbaum D., Jacquemier J., and Sobol H. Novel indications for BRCA1 screening using individual clinical and morphological features. Int. J. Cancer 84 (1999) 263-267
51. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease, 2001. Lancet, 358, 1389-1399.
52. Fejerman L., Haiman C.A., Reich D., Tandon A., Deo R.C., John E.M., Ingles S.A., Ambrosone C.B., Bovbjerg D.H., Jandorf L.H., Davis W., Ciupak G., Whittemore A.S., Press M.F., Ursin G., Bernstein L., Huntsman S., Henderson B.E., Ziv E., and Freedman M.L. An admixture scan in 1484 African American women with breast cancer. Cancer Epidemiol. Biomarkers Prev. 18 (2009) 3110-3117
53. Ford D., Easton D.F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D.T., Weber B., Lenoir G., Chang-Claude J., Sobol H., Teare M.D., Struewing J., Arason A., Scherneck S., Peto J., Rebbeck T.R., Tonin P., Neuhausen S., Barkardottir R., Eyfjord J., Lynch H., Ponder B.A., Gayther S.A., and Zelada-Hedman M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62 (1998) 676-689
54. Foulkes W.D., Metcalfe K., Sun P., Hanna W.M., Lynch H.T., Ghadirian P., Tung N., Olopade O.I., Weber B.L., McLennan J., Olivotto I.A., Begin L.R., and Narod S.A. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin. Cancer Res. 10 (2004) 2029-2034
55. Frank B., Rigas S.H., Bermejo J.L., Wiestler M., Wagner K., Hemminki K., Reed M.W., Sutter C., Wappenschmidt B., Balasubramanian S.P., Meindl A., Kiechle M., Bugert P., Schmutzler R.K., Bartram C.R., Justenhoven C., Ko Y.D., Bruning T., Brauch H., Hamann U., Pharoah P.P., Dunning A.M., Pooley K.A., Easton D.F., Cox A., and Burwinkel B. The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res. Treat. 111 (2008) 139-144
56. Friebel T.M., Domchek S.M., Neuhausen S.L., Wagner T., Evans D.G., Isaacs C., Garber J.E., Daly M.B., Eeles R., Matloff E., Tomlinson G., Lynch H.T., Tung N., Blum J.L., Weitzel J., Rubinstein W.S., Ganz P.A., Couch F., and Rebbeck T.R. Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin. Breast Cancer 7 (2007) 875-882
57. Fulda S. Caspase-8 in cancer biology and therapy. Cancer Lett. 281 (2009) 128-133
58. Gail M.H. Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model. J. Natl. Cancer Inst. 101 (2009) 959-963
59. Garber J.E., Goldstein A.M., Kantor A.F., Dreyfus M.G., Fraumeni Jr. J.F., and Li F.P. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res. 51 (1991) 6094-6097
60. Garcia-Closas M., and Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin. Cancer Res. 14 (2008) 8000-8009
61. Garcia-Closas M., Brinton L.A., Lissowska J., Chatterjee N., Peplonska B., Anderson W.F., Szeszenia-Dabrowska N., Bardin-Mikolajczak A., Zatonski W., Blair A., Kalaylioglu Z., Rymkiewicz G., Mazepa-Sikora D., Kordek R., Lukaszek S., and Sherman M.E. Established breast cancer risk factors by clinically important tumour characteristics. Br. J. Cancer 95 (2006) 123-129
62. Garcia-Closas M., Hall P., Nevanlinna H., Pooley K., Morrison J., Richesson D.A., Bojesen S.E., Nordestgaard B.G., Axelsson C.K., Arias J.I., Milne R.L., Ribas G., Gonzalez-Neira A., Benitez J., Zamora P., Brauch H., Justenhoven C., Hamann U., Ko Y.D., Bruening T., Haas S., Dork T., Schurmann P., Hillemanns P., Bogdanova N., Bremer M., Karstens J.H., Fagerholm R., Aaltonen K., Aittomaki K., von S.K., Blomqvist C., Mannermaa A., Uusitupa M., Eskelinen M., Tengstrom M., Kosma V.M., Kataja V., Chenevix-Trench G., Spurdle A.B., Beesley J., Chen X., Australian Ovarian Cancer Management Group, Kathleen Cuningham Foundation Consortium For Research Into Familial Breast Cancer, Devilee P., van Asperen C.J., Jacobi C.E., Tollenaar R.A., Huijts P.E., Klijn J.G., Chang-Claude J., Kropp S., Slanger T., Flesch-Janys D., Mutschelknauss E., Salazar R., Wang-Gohrke S., Couch F., Goode E.L., Olson J.E., Vachon C., Fredericksen Z.S., Giles G.G., Baglietto L., Severi G., Hopper J.L., English D.R., Southey M.C., Haiman C.A., Henderson B.E., Kolonel L.N., Le M.L., Stram D.O., Hunter D.J., Hankinson S.E., Cox D.G., Tamimi R., Kraft P., Sherman M.E., Chanock S.J., Lissowska J., Brinton L.A., Peplonska B., Klijn J.G., Hooning M.J., Meijers-Heijboer H., Collee J.M., van den Ouweland A., Uitterlinden A.G., Liu J., Lin L.Y., Yuqing L., Humphreys K., Czene K., Cox A., Balasubramanian S.P., Cross S.S., Reed M.W., Blows F., Driver K., Dunning A., Tyrer J., Ponder B.A., Sangrajrang S., Brennan P., McKay J., Odefrey F., Gabrieau V., Sigurdson A., Doody M., Struewing J.P., Alexander B., Easton D.F., and Pharoah P.D. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet. 4 (2008) e1000054 1-10.
63. Ghoussaini M., and Pharoah P.D. Polygenic susceptibility to breast cancer: current state-of-the-art. Future Oncol. 5 (2009) 689-701
64. Gold B., Kirchhoff T., Stefanov S., Lautenberger J., Viale A., Garber J., Friedman E., Narod S., Olshen A.B., Gregersen P., Kosarin K., Olsh A., Bergeron J., Ellis N.A., Klein R.J., Clark A.G., Norton L., Dean M., Boyd J., and Offit K. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc. Natl. Acad. Sci. USA 105 (2008) 4340-4345
65. Haiman C.A., Garcia R.R., Kolonel L.N., Henderson B.E., Wu A.H., and Le M.L. A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat. Genet. 40 (2008) 259-260
66. Hall J.M., Lee M.K., Newman B., Morrow J.E., Anderson L.A., Huey B., and King M.C. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250 (1990) 1684-1689
67. Hartmann L.C., Sellers T.A., Schaid D.J., Frank T.S., Soderberg C.L., Sitta D.L., Frost M.H., Grant C.S., Donohue J.H., Woods J.E., McDonnell S.K., Vockley C.W., Deffenbaugh A., Couch F.J., and Jenkins R.B. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J. Natl. Cancer Inst. 93 (2001) 1633-1637
68. Hedenfalk I., Duggan D., Chen Y., Radmacher M., Bittner M., Simon R., Meltzer P., Gusterson B., Esteller M., Kallioniemi O.P., Wilfond B., Borg A., Trent J., Raffeld M., Yakhini Z., Ben-Dor A., Dougherty E., Kononen J., Bubendorf L., Fehrle W., Pittaluga S., Gruvberger S., Loman N., Johannsson O., Olsson H., and Sauter G. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344 (2001) 539-548
69. Heikkinen T., Karkkainen H., Aaltonen K., Milne R.L., Heikkila P., Aittomaki K., Blomqvist C., and Nevanlinna H. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin. Cancer Res. 15 (2009) 3214-3222
70. Hemminki A., Markie D., Tomlinson I., Avizienyte E., Roth S., Loukola A., Bignell G., Warren W., Aminoff M., Hoglund P., Jarvinen H., Kristo P., Pelin K., Ridanpaa M., Salovaara R., Toro T., Bodmer W., Olschwang S., Olsen A.S., Stratton M.R., de la Chapelle A., and Aaltonen L.A. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391 (1998) 184-187
71. Hines L.M., Risendal B., Slattery M.L., Baumgartner K.B., Giuliano A.R., and Byers T. Differences in estrogen receptor subtype according to family history of breast cancer among Hispanic, but not non-Hispanic White women. Cancer Epidemiol. Biomarkers Prev. 17 (2008) 2700-2706
72. Hishikawa Y., Tamaru N., Ejima K., Hayashi T., and Koji T. Expression of keratinocyte growth factor and its receptor in human breast cancer: its inhibitory role in the induction of apoptosis possibly through the overexpression of Bcl-2. Arch. Histol. Cytol. 67 (2004) 455-464
73. Hopper J.L., and Carlin J.B. Familial aggregation of a disease consequent upon correlation between relatives in a risk factor measured on a continuous scale. Am. J. Epidemiol. 136 (1992) 1138-1147
74. Howlett N.G., Taniguchi T., Olson S., Cox B., Waisfisz Q., De Die-Smulders C., Persky N., Grompe M., Joenje H., Pals G., Ikeda H., Fox E.A., and D'Andrea A.D. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297 (2002) 606-609
75. Huang W.Y., Newman B., Millikan R.C., Schell M.J., Hulka B.S., and Moorman P.G. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am. J. Epidemiol. 151 (2000) 703-714
76. Jenne D.E., Reimann H., Nezu J., Friedel W., Loff S., Jeschke R., Muller O., Back W., and Zimmer M. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat. Genet. 18 (1998) 38-43
77. Johannsson O.T., Idvall I., Anderson C., Borg A., Barkardottir R.B., Egilsson V., and Olsson H. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur. J. Cancer 33 (1997) 362-371
78. Johnatty S.E., Couch F.J., Fredericksen Z., Tarrell R., Spurdle A.B., Beesley J., Chen X., Gschwantler-Kaulich D., Singer C.F., Fuerhauser C., Fink-Retter A., Domchek S.M., Nathanson K.L., Pankratz V.S., Lindor N.M., Godwin A.K., Caligo M.A., Hopper J., Southey M.C., Giles G.G., Justenhoven C., Brauch H., Hamann U., Ko Y.D., Heikkinen T., Aaltonen K., Aittomaki K., Blomqvist C., Nevanlinna H., Hall P., Czene K., Liu J., Peock S., Cook M., Platte R., Gareth E.D., Lalloo F., Eeles R., Pichert G., Eccles D., Davidson R., Cole T., Cook J., Douglas F., Chu C., Hodgson S., Paterson J., Hogervorst F.B., Rookus M.A., Seynaeve C., Wijnen J., Vreeswijk M., Ligtenberg M., van der Luijt R.B., van Os T.A., Gille H.J., Blok M.J., Issacs C., Humphreys M.K., McGuffog L., Healey S., Sinilnikova O., Antoniou A.C., Easton D.F., and Chenevix-Trench G. No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast Cancer Res. Treat. 117 (2009) 371-379
79. Joslyn S.A. Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res. Treat. 73 (2002) 45-59
80. Karp S.E., Tonin P.N., Begin L.R., Martinez J.J., Zhang J.C., Pollak M.N., and Foulkes W.D. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 80 (1997) 435-441
81. Kauff N.D., Domchek S.M., Friebel T.M., Robson M.E., Lee J., Garber J.E., Isaacs C., Evans D.G., Lynch H., Eeles R.A., Neuhausen S.L., Daly M.B., Matloff E., Blum J.L., Sabbatini P., Barakat R.R., Hudis C., Norton L., Offit K., and Rebbeck T.R. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J. Clin. Oncol. 26 (2008) 1331-1337
82. Key T., Appleby P., Barnes I., and Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl. Cancer Inst. 94 (2002) 606-616
83. King M.C., Marks J.H., and Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 (2003) 643-646
84. Kirchhoff T., Chen Z.Q., Gold B., Pal P., Gaudet M.M., Kosarin K., Levine D.A., Gregersen P., Spencer S., Harlan M., Robson M., Klein R.J., Hudis C.A., Norton L., Dean M., and Offit K. The 6q22.33 locus and breast cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 18 (2009) 2468-2475
85. Kong A., Steinthorsdottir V., Masson G., Thorleifsson G., Sulem P., Besenbacher S., Jonasdottir A., Sigurdsson A., Kristinsson K.T., Jonasdottir A., Frigge M.L., Gylfason A., Olason P.I., Gudjonsson S.A., Sverrisson S., Stacey S.N., Sigurgeirsson B., Benediktsdottir K.R., Sigurdsson H., Jonsson T., Benediktsson R., Olafsson J.H., Johannsson O.T., Hreidarsson A.B., Sigurdsson G., Ferguson-Smith A.C., Gudbjartsson
86. Kuschel B., Auranen A., McBride S., Novik K.L., Antoniou A., Lipscombe J.M., Day N.E., Easton D.F., Ponder B.A., Pharoah P.D., and Dunning A. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum. Mol. Genet. 11 (2002) 1399-1407
87. Kwei K.A., Kung Y., Salari K., Holcomb I.N., and Pollack J.R. Genomic instability in breast cancer: pathogenesis and clinical implications. Mol. Oncol. 4 3 (2010) 255-266
88. Lakhani S.R. The pathology of familial breast cancer: morphological aspects. Breast Cancer Res. 1 (1999) 31-35
89. Lakhani S.R., Jacquemier J., Sloane J.P., Gusterson B.A., Anderson T.J., Van De Vijver M.J., Farid L.M., Venter D., Antoniou A., Storfer-Isser A., Smyth E., Steel C.M., Haites N., Scott R.J., Goldgar D., Neuhausen S., Daly P.A., Ormiston W., McManus R., Scherneck S., Ponder B.A., Ford D., Peto J., Stoppa-Lyonnet D., Bignon Y.J., Struewing J.P., Spurr N.K., Bishop D.T., Klijn J.G., Devilee P., Cornelisse C.J., Lasset C., Lenoir G., Barkardottir R.B., Egilsson V., Hamann U., Chang-Claude J., Sobol H., Weber B., Stratton M.R., and Easton D.F. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 90 (1998) 1138-1145
90. Lakhani S.R., Gusterson B.A., Jacquemier J., Sloane J.P., Anderson T.J., Van De Vijver M.J., Venter D., Freeman A., Antoniou A., McGuffog L., Smyth E., Steel C.M., Haites N., Scott R.J., Goldgar D., Neuhausen S., Daly P.A., Ormiston W., McManus R., Scherneck S., Ponder B.A., Futreal P.A., Peto J., Stoppa-Lyonnet D., Bignon Y.J., and Stratton M.R. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin. Cancer Res. 6 (2000) 782-789
91. Lakhani S.R., Van De Vijver M.J., Jacquemier J., Anderson T.J., Osin P.P., McGuffog L., and Easton D.F. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol. 20 (2002) 2310-2318
92. Lakhani S.R., Manek S., Penault-Llorca F., Flanagan A., Arnout L., Merrett S., McGuffog L., Steele D., Devilee P., Klijn J.G., Meijers-Heijboer H., Radice P., Pilotti S., Nevanlinna H., Butzow R., Sobol H., Jacquemier J., Lyonet D.S., Neuhausen S.L., Weber B., Wagner T., Winqvist R., Bignon Y.J., Monti F., Schmitt F., Lenoir G., Seitz S., Hamman U., Pharoah P., Lane G., Ponder B., Bishop D.T., and Easton D.F. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin. Cancer Res. 10 (2004) 2473-2481
93. Lidereau R., Eisinger F., Champeme M.H., Nogues C., Bieche I., Birnbaum D., Pallud C., Jacquemier J., and Sobol H. Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res. 60 (2000) 1206-1210
94. Loman N., Johannsson O., Bendahl P.O., Borg A., Ferno M., and Olsson H. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 83 (1998) 310-319
95. Luqmani Y.A., Graham M., and Coombes R.C. Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br. J. Cancer 66 (1992) 273-280
96. Lønning P.E. Molecular basis for therapy resistance. Mol. Oncol. 4 3 (2010) 284-300
97. Malkin D. Germline p53 mutations and heritable cancer. Annu. Rev. Genet. 28 (1994) 443-465
98. Masciari S., Larsson N., Senz J., Boyd N., Kaurah P., Kandel M.J., Harris L.N., Pinheiro H.C., Troussard A., Miron P., Tung N., Oliveira C., Collins L., Schnitt S., Garber J.E., and Huntsman D. Germline E-cadherin mutations in familial lobular breast cancer. J. Med. Genet. 44 (2007) 726-731
99. Mavaddat N., Dunning A.M., Ponder B.A., Easton D.F., and Pharoah P.D. Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. Cancer Epidemiol. Biomarkers Prev. 18 (2009) 255-259
100. Mavaddat N., Pharoah P.D., Blows F., Driver K.E., Provenzano E., Thompson D., Macinnis R.J., Shah M., Search S.O., Easton D.F., and Antoniou A.C. Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. Breast Cancer Res. 12 (2010) R10 1--2
101. Meijers-Heijboer H., van G.B., van Putten W.L., Henzen-Logmans S.C., Seynaeve C., Menke-Pluymers M.B., Bartels C.C., Verhoog L.C., van den Ouweland A.M., Niermeijer M.F., Brekelmans C.T., and Klijn J.G. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 345 (2001) 159-164
102. Meijers-Heijboer H., van den Ouweland A., Klijn J., Wasielewski M., de S.A., Oldenburg R., Hollestelle A., Houben M., Crepin E., van Veghel-Plandsoen M., Elstrodt F., van D.C., Bartels C., Meijers C., Schutte M., McGuffog L., Thompson D., Easton D., Sodha N., Seal S., Barfoot R., Mangion J., Chang-Claude J., Eccles D., Eeles R., Evans D.G., Houlston R., Murday V., Narod S., Peretz T., Peto J., Phelan C., Zhang H.X., Szabo C., Devilee P., Goldgar D., Futreal P.A., Nathanson K.L., Weber B., Rahman N., and Stratton M.R. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet. 31 (2002) 55-59
103. Meyer K.B., Maia A.T., O'Reilly M., Teschendorff A.E., Chin S.F., Caldas C., and Ponder B.A. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol. 6 (2008) e108
104. Milne R.L., Benitez J., Nevanlinna H., Heikkinen T., Aittomaki K., Blomqvist C., Arias J.I., Zamora M.P., Burwinkel B., Bartram C.R., Meindl A., Schmutzler R.K., Cox A., Brock I., Elliott G., Reed M.W., Southey M.C., Smith L., Spurdle A.B., Hopper J.L., Couch F.J., Olson J.E., Wang X., Fredericksen Z., Schurmann P., Bremer M., Hillemanns P., Dork T., Devilee P., van Asperen C.J., Tollenaar R.A., Seynaeve C., Hall P., Czene K., Liu J., Li Y., Ahmed S., Dunning A.M., Maranian M., Pharoah P.D., Chenevix-Trench G., Beesley J., Bogdanova N.V., Antonenkova N.N., Zalutsky I.V., Anton-Culver H., Ziogas A., Brauch H., Justenhoven C., Ko Y.D., Haas S., Fasching P.A., Strick R., Ekici A.B., Beckmann M.W., Giles G.G., Severi G., Baglietto L., English D.R., Fletcher O., Johnson N., dos SS I., Peto J., Turnbull C., Hines S., Renwick A., Rahman N., Nordestgaard B.G., Bojesen S.E., Flyger H., Kang D., Yoo K.Y., Noh D.Y., Mannermaa A., Kataja V., Kosma V.M., Garcia-Closas M., Chanock S., Lissowska J., Brinton L.A., Chang-Claude J., Wang-Gohrke S., Shen C.Y., Wang H.C., Yu J.C., Chen S.T., Bermisheva M., Nikolaeva T., Khusnutdinova E., Humphreys M.K., Morrison J., Platte R., and Easton D.F. Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J. Natl. Cancer Inst. 101 (2009) 1012-1018
105. Milne R.L., Osorio A., Cajal T., Baiget M., Lasa A., Diaz-Rubio E., de la Hoya M., Caldes T., Teule A., Lazaro C., Blanco I., Balmana J., Sanchez-Olle G., Vega A., Blanco A., Chirivella I., Esteban C.E., Duran M., Velasco E., Martinez de D.E., Tejada M.I., Miramar M.D., Calvo M.T., Guillen-Ponce C., Salazar R., San R.C., Urioste M., and Benitez J. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 119 (2010) 221-232
106. Moffa A.B., Tannheimer S.L., and Ethier S.P. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol. Cancer Res. 2 (2004) 643-652
107. Narod S.A. Modifiers of risk of hereditary breast and ovarian cancer. Nat. Rev. Cancer 2 (2002) 113-123
108. Navin N.E., and Hicks J. Tracing the tumor lineage. Mol. Oncol. 4 3 (2010) 267-283
109. Nelen M.R., Padberg G.W., Peeters E.A., Lin A.Y., van den Helm B., Frants R.R., Coulon V., Goldstein A.M., van Reen M.M., Easton D.F., Eeles R.A., Hodgsen S., Mulvihill J.J., Murday V.A., Tucker M.A., Mariman E.C., Starink T.M., Ponder B.A., Ropers H.H., Kremer H., Longy M., and Eng C. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat. Genet. 13 (1996) 114-116
110. O'Flaherty E., and Kaye J. TOX defines a conserved subfamily of HMG-box proteins. BMC Genomics 4 (2003) 13-
111. Osin P.P., and Lakhani S.R. The pathology of familial breast cancer: immunohistochemistry and molecular analysis. Breast Cancer Res. 1 (1999) 36-40
112. Osorio A., de la Hoya M., Rodriguez-Lopez R., Martinez-Ramirez A., Cazorla A., Granizo J.J., Esteller M., Rivas C., Caldes T., and Benitez J. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int. J. Cancer 99 (2002) 305-309
113. Osorio A., Milne R.L., Pita G., Peterlongo P., Heikkinen T., Simard J., Chenevix-Trench G., Spurdle A.B., Beesley J., Chen X., Healey S., Neuhausen S.L., Ding Y.C., Couch F.J., Wang X., Lindor N., Manoukian S., Barile M., Viel A., Tizzoni L., Szabo C.I., Foretova L., Zikan M., Claes K., Greene M.H., Mai P., Rennert G., Lejbkowicz F., Barnett-Griness O., Andrulis I.L., Ozcelik H., Weerasooriya N., Gerdes A.M., Thomassen M., Cruger D.G., Caligo M.A., Friedman E., Kaufman B., Laitman Y., Cohen S., Kontorovich T., Gershoni-Baruch R., Dagan E., Jernstrom H., Askmalm M.S., Arver B., Malmer B., Domchek S.M., Nathanson K.L., Brunet J., Ramon Y.C., Yannoukakos D., Hamann U., Hogervorst F.B., Verhoef S., Gomez Garcia E.B., Wijnen J.T., van den Ouweland A., Easton D.F., Peock S., Cook M., Oliver C.T., Frost D., Luccarini C., Evans D.G., Lalloo F., Eeles R., Pichert G., Cook J., Hodgson S., Morrison P.J., Douglas F., Godwin A.K., Sinilnikova O.M., Barjhoux L., Stoppa-Lyonnet D., Moncoutier V., Giraud S., Cassini C., Olivier-Faivre L., Revillion F., Peyrat J.P., Muller D., Fricker J.P., Lynch H.T., John E.M., Buys S., Daly M., Hopper J.L., Terry M.B., Miron A., Yassin Y., Goldgar D., Singer C.F., Gschwantler-Kaulich D., Pfeiler G., Spiess A.C., Hansen T.V., Johannsson O.T., Kirchhoff T., Offit K., Kosarin K., Piedmonte M., Rodriguez G.C., Wakeley K., Boggess J.F., Basil J., Schwartz P.E., Blank S.V., Toland A.E., Montagna M., Casella C., Imyanitov E.N., Allavena A., Schmutzler R.K., Versmold B., Engel C., Meindl A., Ditsch N., Arnold N., Niederacher D., Deissler H., Fiebig B., Varon-Mateeva R., Schaefer D., Froster U.G., Caldes T., de la Hoya M., McGuffog L., Antoniou A.C., Nevanlinna H., Radice P., and Benitez J. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). Br. J. Cancer 101 (2009) 2048-2054
114. Palacios J., Honrado E., Osorio A., Cazorla A., Sarrio D., Barroso A., Rodriguez S., Cigudosa J.C., Diez O., Alonso C., Lerma E., Sanchez L., Rivas C., and Benitez J. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin. Cancer Res. 9 (2003) 3606-3614
115. Parkin D.M., Whelan S., Ferlay J., Teppo L., and Thomas D.B. Cancer Incidence in Five Continents vol. VIII (2002)
116. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium, 1997. Lancet, 349, 1505-1510.
117. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., et al. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
118. Peto J., and Mack T.M. High constant incidence in twins and other relatives of women with breast cancer. Nat. Genet. 26 (2000) 411-414
119. Pharoah P.D., Lipscombe J.M., Redman K.L., Day N.E., Easton D.F., and Ponder B.A. Familial predisposition to breast cancer in a British population: implications for prevention. Eur. J. Cancer 36 (2000) 773-779
120. Pharoah P.D., Antoniou A., Bobrow M., Zimmern R.L., Easton D.F., and Ponder B.A. Polygenic susceptibility to breast cancer and implications for prevention. Nat. Genet. 31 (2002) 33-36
121. Pharoah P.D., Antoniou A.C., Easton D.F., and Ponder B.A. Polygenes, risk prediction, and targeted prevention of breast cancer. N. Engl. J. Med. 358 (2008) 2796-2803
122. Phillips K.A. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J. Clin. Oncol. 18 (2000) 107S-112S
123. Podo F., Buydens L.M.C., Degani H., Hilhorst R., Klipp E., Gribbestad I.S., vanHuffel S., vanLaarhoven H.W.M., Luts J., Monleon D., Postma G.J., Schneiderhan-Marra N., Santoro F., Wouters H., Russnes H.G., Sørlie T., Tagliabue E., and Børresen-Dale A.-L. Triple-negative breast cancer: Present challenges and new perspectives. Mol. Oncol. 4 3 (2010) 209-229
124. Potter J.D., Cerhan J.R., Sellers T.A., McGovern P.G., Drinkard C., Kushi L.R., and Folsom A.R. Progesterone and estrogen receptors and mammary neoplasia in the Iowa women's health study: how many kinds of breast cancer are there?. Cancer Epidemiol. Biomarkers Prev. 4 (1995) 319-326
125. Rahman N., Seal S., Thompson D., Kelly P., Renwick A., Elliott A., Reid S., Spanova K., Barfoot R., Chagtai T., Jayatilake H., McGuffog L., Hanks S., Evans D.G., Eccles D., Easton D.F., and Stratton M.R. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 39 (2007) 165-167
126. Rebbeck T.R., Lynch H.T., Neuhausen S.L., Narod S.A., Van't Veer L., Garber J.E., Evans G., Isaacs C., Daly M.B., Matloff E., Olopade O.I., and Weber B.L. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346 (2002) 1616-1622
127. Rebbeck T.R., Friebel T., Lynch H.T., Neuhausen S.L., van ' V., Garber J.E., Evans G.R., Narod S.A., Isaacs C., Matloff E., Daly M.B., Olopade O.I., and Weber B.L. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J. Clin. Oncol. 22 (2004) 1055-1062
128. Rebbeck T.R., Antoniou A.C., Llopis T.C., Nevanlinna H., Aittomaki K., Simard J., Spurdle A.B., Couch F.J., Pereira L.H., Greene M.H., Andrulis I.L., Pasche B., Kaklamani V., Hamann U., Szabo C., Peock S., Cook M., Harrington P.A., Donaldson A., Male A.M., Gardiner C.A., Gregory H., Side L.E., Robinson A.C., Emmerson L., Ellis I., Peyrat J.P., Fournier J., Vennin P., Adenis C., Muller D., Fricker J.P., Longy M., Sinilnikova O.M., Stoppa-Lyonnet D., Schmutzler R.K., Versmold B., Engel C., Meindl A., Kast K., Schaefer D., Froster U.G., Chenevix-Trench G., and Easton D.F. No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. Breast Cancer Res. Treat. 115 (2009) 185-192
129. Rebbeck T.R., Kauff N.D., and Domchek S.M. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J. Natl. Cancer Inst. 101 (2009) 80-87
130. Renwick A., Thompson D., Seal S., Kelly P., Chagtai T., Ahmed M., North B., Jayatilake H., Barfoot R., Spanova K., McGuffog L., Evans D.G., Eccles D., Easton D.F., Stratton M.R., and Rahman N. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat. Genet. 38 (2006) 873-875
131. Ridolfi R.L., Rosen P.P., Port A., Kinne D., and Mike V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 40 (1977) 1365-1385
132. Rosenberg L.U., Einarsdottir K., Friman E.I., Wedren S., Dickman P.W., Hall P., and Magnusson C. Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 2482-2488
133. Ruiz-Narvaez E.A., Rosenberg L., Rotimi C.N., Cupples L.A., Boggs D.A., Adeyemo A., Cozier Y.C., Adams-Campbell L.L., and Palmer J.R. Genetic variants on chromosome 5p12 are associated with risk of breast cancer in African American women: the black women's health study. Breast Cancer Res. Treat. (2010)
134. Rusiecki J.A., Holford T.R., Zahm S.H., and Zheng T. Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status. Cancer Detect Prev 29 (2005) 419-426
135. Scully R., Chen J., Plug A., Xiao Y., Weaver D., Feunteun J., Ashley T., and Livingston D.M. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88 (1997) 265-275
136. Seal S., Thompson D., Renwick A., Elliott A., Kelly P., Barfoot R., Chagtai T., Jayatilake H., Ahmed M., Spanova K., North B., McGuffog L., Evans D.G., Eccles D., Easton D.F., Stratton M.R., and Rahman N. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet. 38 (2006) 1239-1241
137. Surveillance, Epidemiology, and End Results (SEER) Program Limited-Use Data (1973-2006), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, Released April 2009, based on the November 2008 submission. 9 A.D
138. Sherman M.E., Rimm D.L., Yang X.R., Chatterjee N., Brinton L.A., Lissowska J., Peplonska B., Szeszenia-Dabrowska N., Zatonski W., Cartun R., Mandich D., Rymkiewicz G., Ligaj M., Lukaszek S., Kordek R., Kalaylioglu Z., Harigopal M., Charrette L., Falk R.T., Richesson D., Anderson W.F., Hewitt S.M., and Garcia-Closas M. Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: a population-based analysis. Int. J. Cancer 121 (2007) 1079-1085
139. Sinilnikova O.M., Antoniou A.C., Simard J., Healey S., Leone M., Sinnett D., Spurdle A.B., Beesley J., Chen X., Greene M.H., Loud J.T., Lejbkowicz F., Rennert G., Dishon S., Andrulis I.L., Domchek S.M., Nathanson K.L., Manoukian S., Radice P., Konstantopoulou I., Blanco I., Laborde A.L., Duran M., Osorio A., Benitez J., Hamann U., Hogervorst F.B., van Os T.A., Gille H.J., Peock S., Cook M., Luccarini C., Evans D.G., Lalloo F., Eeles R., Pichert G., Davidson R., Cole T., Cook J., Paterson J., Brewer C., Hughes D.J., Coupier I., Giraud S., Coulet F., Colas C., Soubrier F., Rouleau E., Bieche I., Lidereau R., Demange L., Nogues C., Lynch H.T., Schmutzler R.K., Versmold B., Engel C., Meindl A., Arnold N., Sutter C., Deissler H., Schaefer D., Froster U.G., Aittomaki K., Nevanlinna H., McGuffog L., Easton D.F., Chenevix-Trench G., and Stoppa-Lyonnet D. The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br. J. Cancer 101 (2009) 1456-1460
140. Smid M., Wang Y., Klijn J.G., Sieuwerts A.M., Zhang Y., Atkins D., Martens J.W., and Foekens J.A. Genes associated with breast cancer metastatic to bone. J. Clin. Oncol. 24 (2006) 2261-2267
141. Smith P., McGuffog L., Easton D.F., Mann G.J., Pupo G.M., Newman B., Chenevix-Trench G., Szabo C., Southey M., Renard H., Odefrey F., Lynch H., Stoppa-Lyonnet D., Couch F., Hopper J.L., Giles G.G., McCredie M.R., Buys S., Andrulis I., Senie R., Goldgar D.E., Oldenburg R., Kroeze-Jansema K., Kraan J., Meijers-Heijboer H., Klijn J.G., van A.C., van L.I., Vasen H.F., Cornelisse C.J., Devilee P., Baskcomb L., Seal S., Barfoot R., Mangion J., Hall A., Edkins S., Rapley E., Wooster R., Chang-Claude J., Eccles D., Evans D.G., Futreal P.A., Nathanson K.L., Weber B.L., Rahman N., and Stratton M.R. A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 45 (2006) 646-655
142. Song H., Ramus S.J., Tyrer J., Bolton K.L., Gentry-Maharaj A., Wozniak E., Anton-Culver H., Chang-Claude J., Cramer D.W., DiCioccio R., Dork T., Goode E.L., Goodman M.T., Schildkraut J.M., Sellers T., Baglietto L., Beckmann M.W., Beesley J., Blaakaer J., Carney M.E., Chanock S., Chen Z., Cunningham J.M., Dicks E., Doherty J.A., Durst M., Ekici A.B., Fenstermacher D., Fridley B.L., Giles G., Gore M.E., De V I., Hillemanns P., Hogdall C., Hogdall E., Iversen E.S., Jacobs I.J., Jakubowska A., Li D., Lissowska J., Lubinski J., Lurie G., McGuire V., McLaughlin J., Medrek K., Moorman P.G., Moysich K., Narod S., Phelan C., Pye C., Risch H., Runnebaum I.B., Severi G., Southey M., Stram D.O., Thiel F.C., Terry K.L., Tsai Y.Y., Tworoger S.S., Van Den Berg D.J., Vierkant R.A., Wang-Gohrke S., Webb P.M., Wilkens L.R., Wu A.H., Yang H., Brewster W., Ziogas A., Houlston R., Tomlinson I., Whittemore A.S., Rossing M.A., Ponder B.A., Pearce C.L., Ness R.B., Menon U., Kjaer S.K., Gronwald J., Garcia-Closas M., Fasching P.A., Easton D.F., Chenevix-Trench G., Berchuck A., Pharoah P.D., and Gayther S.A. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat. Genet. 41 (2009) 996-1000
143. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C.M., Lonning P.E., Brown P.O., Borresen-Dale A.L., and Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U S A 100 (2003) 8418-8423
144. Spurdle A.B., Antoniou A.C., Kelemen L., Holland H., Peock S., Cook M.R., Smith P.L., Greene M.H., Simard J., Plourde M., Southey M.C., Godwin A.K., Beck J., Miron A., Daly M.B., Santella R.M., Hopper J.L., John E.M., Andrulis I.L., Durocher F., Struewing J.P., Easton D.F., and Chenevix-Trench G. The AIB1 polyglutamine repeat does not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 76-79
145. Spurdle A.B., Deans A.J., Duffy D., Goldgar D.E., Chen X., Beesley J., Easton D.F., Antoniou A.C., Peock S., Cook M., Nathanson K.L., Domchek S.M., MacArthur G.A., and Chenevix-Trench G. No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 115 (2009) 307-313
146. Spurdle A.B., Fahey P., Chen X., McGuffog L., Easton D., Peock S., Cook M., Simard J., Rebbeck T.R., Antoniou A.C., and Chenevix-Trench G. Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. (2009)
147. Stacey S.N., Manolescu A., Sulem P., Rafnar T., Gudmundsson J., Gudjonsson S.A., Masson G., Jakobsdottir M., Thorlacius S., Helgason A., Aben K.K., Strobbe L.J., Albers-Akkers M.T., Swinkels D.W., Henderson B.E., Kolonel L.N., Le M.L., Millastre E., Andres R., Godino J., Garcia-Prats M.D., Polo E., Tres A., Mouy M., Saemundsdottir J., Backman V.M., Gudmundsson L., Kristjansson K., Bergthorsson J.T., Kostic J., Frigge M.L., Geller F., Gudbjartsson D., Sigurdsson H., Jonsdottir T., Hrafnkelsson J., Johannsson J., Sveinsson T., Myrdal G., Grimsson H.N., Jonsson T., von H.S., Werelius B., Margolin S., Lindblom A., Mayordomo J.I., Haiman C.A., Kiemeney L.A., Johannsson O.T., Gulcher J.R., Thorsteinsdottir U., Kong A., and Stefansson K. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 39 (2007) 865-869
148. Stacey S.N., Manolescu A., Sulem P., Thorlacius S., Gudjonsson S.A., Jonsson G.F., Jakobsdottir M., Bergthorsson J.T., Gudmundsson J., Aben K.K., Strobbe L.J., Swinkels D.W., van Engelenburg K.C., Henderson B.E., Kolonel L.N., Le M.L., Millastre E., Andres R., Saez B., Lambea J., Godino J., Polo E., Tres A., Picelli S., Rantala J., Margolin S., Jonsson T., Sigurdsson H., Jonsdottir T., Hrafnkelsson J., Johannsson J., Sveinsson T., Myrdal G., Grimsson H.N., Sveinsdottir S.G., Alexiusdottir K., Saemundsdottir J., Sigurdsson A., Kostic J., Gudmundsson L., Kristjansson K., Masson G., Fackenthal J.D., Adebamowo C., Ogundiran T., Olopade O.I., Haiman C.A., Lindblom A., Mayordomo J.I., Kiemeney L.A., Gulcher J.R., Rafnar T., Thorsteinsdottir U., Johannsson O.T., Kong A., and Stefansson K. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 40 (2008) 703-706
149. Sun T., Gao Y., Tan W., Ma S., Shi Y., Yao J., Guo Y., Yang M., Zhang X., Zhang Q., Zeng C., and Lin D. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat. Genet. 39 (2007) 605-613
150. Tamaru N., Hishikawa Y., Ejima K., Nagasue N., Inoue S., Muramatsu M., Hayashi T., and Koji T. Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer. Lab. Invest. 84 (2004) 1460-1471
151. Teo Y.Y., Small K.S., and Kwiatkowski D.P. Methodological challenges of genome-wide association analysis in Africa. Nat. Rev. Genet. 11 (2010) 149-160
152. Thomas G., Jacobs K.B., Kraft P., Yeager M., Wacholder S., Cox D.G., Hankinson S.E., Hutchinson A., Wang Z., Yu K., Chatterjee N., Garcia-Closas M., Gonzalez-Bosquet J., Prokunina-Olsson L., Orr N., Willett W.C., Colditz G.A., Ziegler R.G., Berg C.D., Buys S.S., McCarty C.A., Feigelson H.S., Calle E.E., Thun M.J., Diver R., Prentice R., Jackson R., Kooperberg C., Chlebowski R., Lissowska J., Peplonska B., Brinton L.A., Sigurdson A., Doody M., Bhatti P., Alexander B.H., Buring J., Lee I.M., Vatten L.J., Hveem K., Kumle M., Hayes R.B., Tucker M., Gerhard D.S., Fraumeni Jr. J.F., Hoover R.N., Chanock S.J., and Hunter D.J. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat. Genet. 41 (2009) 579-584
153. Thompson D., and Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am. J. Hum. Genet. 68 (2001) 410-419
154. Thompson D., and Easton D. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 329-336
155. Thompson D., and Easton D. The genetic epidemiology of breast cancer genes. J. Mammary Gland Biol. Neoplasia 9 (2004) 221-236
156. Turnbull C., and Rahman N. Genetic predisposition to breast cancer: past, present, and future. Annu. Rev. Genomics Hum. Genet. 9 (2008) 321-345
157. Tutera A.M., Sellers T.A., Potter J.D., Drinkard C.R., Wiesner G.L., and Folsom A.R. Association between family history of cancer and breast cancer defined by estrogen and progesterone receptor status. Genet. Epidemiol. 13 (1996) 207-221
158. Udler M.S., Meyer K.B., Pooley K.A., Karlins E., Struewing J.P., Zhang J., Doody D.R., MacArthur S., Tyrer J., Pharoah P.D., Luben R., Bernstein L., Kolonel L.N., Henderson B.E., Le M.L., Ursin G., Press M.F., Brennan P., Sangrajrang S., Gaborieau V., Odefrey F., Shen C.Y., Wu P.E., Wang H.C., Kang D., Yoo K.Y., Noh D.Y., Ahn S.H., Ponder B.A., Haiman C.A., Malone K.E., Dunning A.M., Ostrander E.A., and Easton D.F. FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum. Mol. Genet. 18 (2009) 1692-1703
159. Wacholder S., Hartge P., Prentice R., Garcia-Closas M., Feigelson H.S., Diver W.R., Thun M.J., Cox D.G., Hankinson S.E., Kraft P., Rosner B., Berg C.D., Brinton L.A., Lissowska J., Sherman M.E., Chlebowski R., Kooperberg C., Jackson R.D., Buckman D.W., Hui P., Pfeiffer R., Jacobs K.B., Thomas G.D., Hoover R.N., Gail M.H., Chanock S.J., and Hunter D.J. Performance of common genetic variants in breast-cancer risk models. N. Engl. J. Med 362 (2010) 986-993
160. Webb P.M., Hopper J.L., Newman B., Chen X., Kelemen L., Giles G.G., Southey M.C., Chenevix-Trench G., and Spurdle A.B. Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 319-323
161. Weigelt B., Geyer F.C., and Reis-Filho J.S. Histological types of breast cancer: How special are they?. Mol. Oncol. 4 3 (2010) 192-208
162. Welsh M.L., Buist D.S., Aiello Bowles E.J., Anderson M.L., Elmore J.G., and Li C.I. Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history. Breast Cancer Res. Treat. 114 (2009) 549-558
163. Wong A.K., Pero R., Ormonde P.A., Tavtigian S.V., and Bartel P.L. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J. Biol. Chem. 272 (1997) 31941-31944
164. Wooster R., Neuhausen S.L., Mangion J., Quirk Y., Ford D., Collins N., Nguyen K., Seal S., Tran T., and Averill D. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265 (1994) 2088-2090
165. Yang X.R., Pfeiffer R.M., Garcia-Closas M., Rimm D.L., Lissowska J., Brinton L.A., Peplonska B., Hewitt S.M., Cartun R.W., Mandich D., Sasano H., Evans D.B., Sutter T.R., and Sherman M.E. Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. Cancer Res. 67 (2007) 10608-10617
166. Yehiely F., Moyano J.V., Evans J.R., Nielsen T.O., and Cryns V.L. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol. Med. 12 (2006) 537-544
167. Zang X.P., and Pento J.T. Keratinocyte growth factor-induced motility of breast cancer cells. Clin. Exp. Metastasis 18 (2000) 573-580
168. Zeggini E., Scott L.J., Saxena R., Voight B.F., Marchini J.L., Hu T., de Bakker P.I., Abecasis G.R., Almgren P., Andersen G., Ardlie K., Bostrom K.B., Bergman R.N., Bonnycastle L.L., Borch-Johnsen K., Burtt N.P., Chen H., Chines P.S., Daly M.J., Deodhar P., Ding C.J., Doney A.S., Duren W.L., Elliott K.S., Erdos M.R., Frayling T.M., Freathy R.M., Gianniny L., Grallert H., Grarup N., Groves C.J., Guiducci C., Hansen T., Herder C., Hitman G.A., Hughes T.E., Isomaa B., Jackson A.U., Jorgensen T., Kong A., Kubalanza K., Kuruvilla F.G., Kuusisto J., Langenberg C., Lango H., Lauritzen T., Li Y., Lindgren C.M., Lyssenko V., Marvelle A.F., Meisinger C., Midthjell K., Mohlke K.L., Morken M.A., Morris A.D., Narisu N., Nilsson P., Owen K.R., Palmer C.N., Payne F., Perry J.R., Pettersen E., Platou C., Prokopenko I., Qi L., Qin L., Rayner N.W., Rees M., Roix J.J., Sandbaek A., Shields B., Sjogren M., Steinthorsdottir V., Stringham H.M., Swift A.J., Thorleifsson G., Thorsteinsdottir U., Timpson N.J., Tuomi T., Tuomilehto J., Walker M., Watanabe R.M., Weedon M.N., Willer C.J., Illig T., Hveem K., Hu F.B., Laakso M., Stefansson K., Pedersen O., Wareham N.J., Barroso I., Hattersley A.T., Collins F.S., Groop L., McCarthy M.I., Boehnke M., and Altshuler D. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat. Genet. 40 (2008) 638-645
169. Zhang Y., Kulp S.K., Sugimoto Y., Farrar W.B., Brueggemeier R.W., and Lin Y.C. Keratinocyte growth factor (KGF) induces aromatase activity in cultured MCF-7 human breast cancer cells. Anticancer Res. 18 (1998) 2541-2546
170. Zhang Y., Sugimoto Y., Kulp S.K., Farrar W.B., Brueggemeier R.W., and Lin Y.C. Estrogen-induced keratinocyte growth factor mRNA expression in normal and cancerous human breast cells. Oncol. Rep. 5 (1998) 577-583
171. Zheng W., Cai Q., Signorello L.B., Long J., Hargreaves M.K., Deming S.L., Li G., Li C., Cui Y., and Blot W.J. Evaluation of 11 breast cancer susceptibility loci in African-American women. Cancer Epidemiol. Biomarkers Prev. 18 (2009) 2761-2764
172. Zheng W., Long J., Gao Y.T., Li C., Zheng Y., Xiang Y.B., Wen W., Levy S., Deming S.L., Haines J.L., Gu K., Fair A.M., Cai Q., Lu W., and Shu X.O. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat. Genet. 41 (2009) 324-328